Skip to main content
ARS Home » Southeast Area » Athens, Georgia » U.S. National Poultry Research Center » Endemic Poultry Viral Diseases Research » Research » Publications at this Location » Publication #295958
Title: Recombinant Newcastle disease virus Anhinga Strain (NDV/Anh-EGFP) for Hepatoma Therapy

Author
item WU, YUNZHOU - Northeast Agricultural University
item YAN, SHIJUN - Northeast Agricultural University
item LV, ZHENG - Northeast Agricultural University
item CHEN, LIN - Harbin Veterinary Research Institute
item GENG, JINGSHU - Harbin Veterinary Research Institute
item HE, JINJIAO - Northeast Agricultural University
item Yu, Qingzhong
item YIN, JECHAO - Northeast Agricultural University
item REN, GUIPING - Northeast Agricultural University
item LI, DESHAN - Northeast Agricultural University

Submitted to: Technology in Cancer Research and Treatment
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 12/1/2013
Publication Date: 4/1/2014
Publication URL: http://handle.nal.usda.gov/10113/60111
Citation: Wu, Y., Yan, S., Lv, Z., Chen, L., Geng, J., He, J., Yu, Q., Yin, J., Ren, G., Li, D. 2014. Recombinant Newcastle disease virus Anhinga Strain (NDV/Anh-EGFP) for Hepatoma Therapy. Technology in Cancer Research and Treatment. 13:169-175.

Interpretive Summary: Hepatocellular carcinoma, known as liver cancer, is the most common life-killing tumors in the world. Unfortunately there is no effective treatment of the tumor disease. Newcastle disease virus (NDV), an avian disease pathogen, has been proved to be an efficient cancer cells killing, or oncolytic, agent. NDV tumor killing efficacy is not only depending on the NDV strain but also the type of tumor targeted. In the present study, we investigated the effectiveness of genetically engineered NDV Anhinga strain in liver cancer or hepatoma treatment. The modified virus contained an enhanced green fluorescent protein (EGFP) gene as a marker, which was named as NDV/Anh-EGFP. The antitumor efficacy of the recombinant virus on hepatoma was examined both in cell cultures and in mice. The results showed that the NDV Anhinga strain was effective in killing liver cancer cells. There was no obvious difference of the growth capability between the recombinant NDV and the parental virus in the cancer cells. NDV/Anh-EGFP significantly inhibited liver cancer development both in cancer cell lines and in mice. Our results suggest that NDV Anhinga strain could become a potent candidate for clinical carcinoma therapy especially for liver cancer.

Technical Abstract: Hepatocellular carcinoma remains one of the most common malignant tumors in the world. Newcastle disease virus (NDV) has been proved to be an efficient oncolytic agent. NDV tumor killing efficacy is not only depending on the NDV strain but the type of tumor targeted. It is significant to discover more effective and safe oncolytic strains. We investigated the effectiveness of genetically engineered NDV Anhinga strain in hepatoma treatment. The modified virus contained an insertion of enhanced green fluorescent protein (EGFP), named NDV/Anh-EGFP. The antitumor efficacy of the recombinant virus on hepatoma was examined both in vivo and in vitro. NDV Anhinga strain, which could be classified as a lytic strain, is an effective oncolytic agent on hepatoma. There was no obvious difference in the TCID50 and growth capability between the recombinant NDV and the parental virus. NDV/Anh-EGFP can significantly inhibit hepatocarcinoma development in vitro and in vivo. We demonstrate Anhinga strain could become a potent candidate for clinical carcinoma therapy especially for hepatocarcinoma.